🔎 Trials Near Me

Почетна › Езофагеален аденокарцином › Тексас

Клинички испитувања за Езофагеален аденокарцином во Тексас

19 студии за Езофагеален аденокарцином бараат учесници на локации во Тексас.

Градови во Тексас

Официјален текст на студијата (англиски)

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06203600

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • Parkland Memorial Hospital, Dallas
  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • и уште 3
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT05677490

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center - Conroe, Conroe
  • University of Texas MD Anderson Cancer Center, Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston, Houston
  • и уште 3
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07090499

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06324357

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  • Texas Oncology - Amarillo Cancer Center, Amarillo
  • Texas Oncology-Austin Central, Austin
  • Texas Oncology, Beaumont
  • и уште 4
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07221149

Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  • US Oncology Investigational Products Center (IPC), Irving
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07392892

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • START Dallas Fort Worth, Fort Worth
  • MD Anderson, Houston
  • NEXT Oncology Houston, Houston
  • и уште 1
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07277413

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  • Baylor University Medical Center, Dallas
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 14.9.2026 · NCT06732388

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  • Baylor University Medical Center, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
Се регрутира
Возраст од 18 до 89 · Сите полови · Ажурирано 11.9.2026 · NCT05753748

A Study of KK2269 in Adult Participants With Solid Tumors

  • The University of Texas Southwestern Medical Center, Dallas
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 10.9.2026 · NCT06266299

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  • Research Site, Dallas
  • Research Site, Dallas
  • Research Site, Houston
  • и уште 1
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 9.9.2026 · NCT07431281

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

  • Normunity Investigational Site, Dallas
  • Normunity Investigational Site, Houston
  • Normunity Investigational Site, San Antonio
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 18.8.2026 · NCT07182149

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Texas Oncology - West Texas, Amarillo
  • Texas Oncology, P.A., Dallas
  • Texas Oncology Gulf Coast, Pearland
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 5.8.2026 · NCT06330064

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

  • Texas Oncology - Central South, Austin
  • START San Antonio, LLC., San Antonio
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 15.7.2026 · NCT06657144

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

  • Oncology Consultants, PA, Houston
  • Oncology Consultants, PA., Houston
  • The University of Texas M.D. Anderson Cancer Center, Houston
  • и уште 5
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 6.7.2026 · NCT04389632

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

  • Research Site, San Antonio
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 12.6.2026 · NCT07284186

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

  • MDACC, Houston
  • NEXT Dallas, Irving
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 8.5.2026 · NCT05954312

Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer

  • M D Anderson Cancer Center, Houston
Се регрутираФаза 2
Возраст од 18 до 79 · Сите полови · Ажурирано 15.4.2026 · NCT03161522

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
  • Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 5.11.2025 · NCT05563766

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.